CHRNA7 and schizophrenia: For more than a decade, there has been an increased interest to develop high affinity α7 nAChR-agonists capable to cross the blood-brain barrier and induce or enhance neuroplastic changes in the brain79, 80 for treatment of schizophrenia and Alzheimer’s disease81 as well as nicotine addiction82.